Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News: Apr 14, 2011

Premium

Cepheid said this week that it has received clearance from the US Food and Drug Administration to market its Xpert C. difficile/Epi test.

Cepheid's first Xpert C. difficile test, which only detects C. difficile, has been available in the US since July 2009. The newly approved test additionally and simultaneously identifies the epidemic strain of C. difficile, also known as 027, NAP1, or BI, Cepheid said.

"Compared to less-virulent strains, C. difficile 027 strains produce higher levels of spores, which pose greater infection control challenges," Cepheid CEO John Bishop said in a statement. Bishop also noted that there is a growing body of evidence that the 027 strain is associated with more frequent relapses and ultimately higher mortality rates.

The Xpert C. difficile/Epi test, which runs on the GeneXpert system, is Cepheid's tenth Xpert test to receive FDA clearance. It is expected to be available for shipment in mid-May, the company said.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.